Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 13/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482732 | 0.94 | EPHB4 (0.52) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5488379 | 0.91 | EPHB4 (0.58) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5482208 | 0.88 | EPHB4 (0.60) | EPHB4MAPTPOLBAURKACNR1 | |
| SCHEMBL5488365 | 0.88 | EPHB4 (0.51) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5478322 | 0.88 | EPHB4 (0.62) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5478329 | 0.87 | EPHB4 (0.56) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5485854 | 0.83 | EPHB4 (0.56) | EPHB4AURKA | |
| SCHEMBL5482031 | 0.83 | EPHB4 (0.59) | EPHB4MAPTAURKACNR1 | |
| SCHEMBL6683431 | 0.82 | EPHB4 (0.51) | EPHB4MAPTKDM4EALDH1A1POLB | |
| SCHEMBL5490521 | 0.81 | EPHB4 (0.58) | EPHB4MAPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | claimed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | claimed |
| WO-2004072080-A1 | CERTAIN 8-HETEROARYL-6-PHENYL-IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF HSP90 COMPLEX ACTIVITY | CELLULAR GENOMICS, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160885-B2 | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity | CGI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | XEROX CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054649-A1 | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-A]pyrazines as modulators of Hsp90 complex activity | HSP90AB1, HSP90AA1, HSPA9 | EPHB4 4724/4885MAPT 1253/4885KDM4E 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.